Search

Your search keyword '"Van Le, Linda"' showing total 392 results
Start Over Author "Van Le, Linda"
392 results on '"Van Le, Linda"'

1. The effect of older age on treatment outcomes in women with advanced ovarian cancer receiving chemotherapy: An NRG-Oncology/Gynecologic Oncology Group (GOG-0182-ICON5) ancillary study.

Author

Sia, Tiffany, Tew, William, Purdy, Christopher, Chi, Dennis, Menzin, Andrew, Lovecchio, John, Bookman, Michael, Cohn, David, Teoh, Deanna, Friedlander, Michael, Bender, David, Mutch, David, Gershenson, David, Wenham, Robert, Wahner Hendrickson, Andrea, Lee, Roger, Gray, Heidi, Secord, Angeles, Van Le, Linda, Lichtman, Stuart, and Tewari, Krishnansu

Subjects
Female, Humans, Aged, Carcinoma, Ovarian Epithelial, Carboplatin, Ovarian Neoplasms, Disease-Free Survival, Neoplasms, Glandular and Epithelial, Paclitaxel, Treatment Outcome, Antineoplastic Combined Chemotherapy Protocols, Neoplasm Staging
Abstract

OBJECTIVE: To assess the effect of age on overall survival (OS) in women with ovarian cancer receiving chemotherapy. Secondary objectives were to describe the effect of age on treatment compliance, toxicities, progression free survival (PFS), time from surgery to chemotherapy, and rates of optimal cytoreduction. METHODS: Women enrolled in GOG 0182-ICON5 with stage III or IV epithelial ovarian cancer (EOC) who underwent surgery and chemotherapy between 2001 and 2004 were included. Patients were divided into ages

Published
2023

2. Health-related quality of life in patients with newly diagnosed advanced ovarian cancer treated with niraparib vs placebo: Results from the phase 3 randomized PRIMA/ENGOT-OV26/GOG-3012 trial

Author

Pothuri, Bhavana, Han, Sileny, Chase, Dana M., Heitz, Florian, Burger, Robert A., Gaba, Lydia, Van Le, Linda, Guerra, Eva, Bender, David, Korach, Jacob, Cloven, Noelle, Churruca, Cristina, Follana, Philippe, DiSilvestro, Paul, Baurain, Jean-François, Jardon, Kris, Pisano, Carmela, Peen, Ulla, Mäenpää, Johanna, Gupta, Divya, Bacqué, Emeline, Li, Yong, Compton, Natalie, Antonova, Jenya, Monk, Bradley J., and González-Martín, Antonio

Published
2024
Full Text
View/download PDF

3. Radiotherapy Versus Inguinofemoral Lymphadenectomy as Treatment for Vulvar Cancer Patients With Micrometastases in the Sentinel Node: Results of GROINSS-V II

Author

Oonk, Maaike HM, Slomovitz, Brian, Baldwin, Peter JW, van Doorn, Helena C, van der Velden, Jacobus, de Hullu, Joanne A, Gaarenstroom, Katja N, Slangen, Brigitte FM, Vergote, Ignace, Brännström, Mats, van Dorst, Eleonora BL, van Driel, Willemien J, Hermans, Ralph H, Nunns, David, Widschwendter, Martin, Nugent, David, Holland, Cathrine M, Sharma, Aarti, DiSilvestro, Paul A, Mannel, Robert, Boll, Dorry, Cibula, David, Covens, Al, Provencher, Diane, Runnebaum, Ingo B, Luesley, David, Ellis, Patricia, Duncan, Timothy J, Tjiong, Ming Y, Cruickshank, Derek J, Kjølhede, Preben, Levenback, Charles F, Bouda, Jiri, Kieser, Katharina E, Palle, Connie, Spirtos, Nicola M, O'Malley, David M, Leitao, Mario M, Geller, Melissa A, Dhar, Kalyan, Asher, Viren, Tamussino, Karl, Tobias, Daniel H, Borgfeldt, Christer, Lea, Jayanthi S, Bailey, Jo, Lood, Margareta, Eyjolfsdottir, Brynhildur, Attard-Montalto, Stephen, Tewari, Krishnansu S, Manchanda, Ranjit, Jensen, Pernille T, Persson, Par, Van Le, Linda, Putter, Hein, de Bock, Geertruida H, Monk, Bradley J, Creutzberg, Carien L, and van der Zee, Ate GJ

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Oncology and Carcinogenesis, Clinical Trials and Supportive Activities, Clinical Research, Cancer, Evaluation of treatments and therapeutic interventions, 6.5 Radiotherapy and other non-invasive therapies, Aged, Female, Humans, Lymph Node Excision, Lymphatic Metastasis, Middle Aged, Neoplasm Micrometastasis, Neoplasm Staging, Prospective Studies, Radiation Dosage, Sentinel Lymph Node, Time Factors, Treatment Outcome, Vulvar Neoplasms, Oncology & Carcinogenesis, Oncology and carcinogenesis
Abstract

PurposeThe Groningen International Study on Sentinel nodes in Vulvar cancer (GROINSS-V)-II investigated whether inguinofemoral radiotherapy is a safe alternative to inguinofemoral lymphadenectomy (IFL) in vulvar cancer patients with a metastatic sentinel node (SN).MethodsGROINSS-V-II was a prospective multicenter phase-II single-arm treatment trial, including patients with early-stage vulvar cancer (diameter < 4 cm) without signs of lymph node involvement at imaging, who had primary surgical treatment (local excision with SN biopsy). Where the SN was involved (metastasis of any size), inguinofemoral radiotherapy was given (50 Gy). The primary end point was isolated groin recurrence rate at 24 months. Stopping rules were defined for the occurrence of groin recurrences.ResultsFrom December 2005 until October 2016, 1,535 eligible patients were registered. The SN showed metastasis in 322 (21.0%) patients. In June 2010, with 91 SN-positive patients included, the stopping rule was activated because the isolated groin recurrence rate in this group went above our predefined threshold. Among 10 patients with an isolated groin recurrence, nine had SN metastases > 2 mm and/or extracapsular spread. The protocol was amended so that those with SN macrometastases (> 2 mm) underwent standard of care (IFL), whereas patients with SN micrometastases (≤ 2 mm) continued to receive inguinofemoral radiotherapy. Among 160 patients with SN micrometastases, 126 received inguinofemoral radiotherapy, with an ipsilateral isolated groin recurrence rate at 2 years of 1.6%. Among 162 patients with SN macrometastases, the isolated groin recurrence rate at 2 years was 22% in those who underwent radiotherapy, and 6.9% in those who underwent IFL (P = .011). Treatment-related morbidity after radiotherapy was less frequent compared with IFL.ConclusionInguinofemoral radiotherapy is a safe alternative for IFL in patients with SN micrometastases, with minimal morbidity. For patients with SN macrometastasis, radiotherapy with a total dose of 50 Gy resulted in more isolated groin recurrences compared with IFL.

Published
2021

4. Beyond Sedlis—A novel histology-specific nomogram for predicting cervical cancer recurrence risk: An NRG/GOG ancillary analysis

Author

Levinson, Kimberly, Beavis, Anna L, Purdy, Christopher, Rositch, Anne F, Viswanathan, Akila, Wolfson, Aaron H, Kelly, Michael G, Tewari, Krishnansu S, McNally, Leah, Guntupalli, Saketh R, Ragab, Omar, Lee, Yi-Chun, Miller, David S, Huh, Warner K, Wilkinson, Kelly J, Spirtos, Nicola M, Van Le, Linda, Casablanca, Yovanni, Holman, Laura L, Waggoner, Steven E, and Fader, Amanda N

Subjects
Cancer, Adenocarcinoma, Adult, Carcinoma, Squamous Cell, Female, Humans, Middle Aged, Neoplasm Invasiveness, Neoplasm Recurrence, Local, Neoplasm Staging, Nomograms, Proportional Hazards Models, Randomized Controlled Trials as Topic, Risk Factors, Uterine Cervical Neoplasms, Cervical cancer, Stage I, Adjuvant radiation, Oncology and Carcinogenesis, Paediatrics and Reproductive Medicine, Oncology & Carcinogenesis
Abstract

PurposeThe Sedlis criteria define risk factors for recurrence warranting post-hysterectomy radiation for early-stage cervical cancer; however, these factors were defined for squamous cell carcinoma (SCC) at an estimated recurrence risk of ≥30%. Our study evaluates and compares risk factors for recurrence for cervical SCC compared with adenocarcinoma (AC) and develops histology-specific nomograms to estimate risk of recurrence and guide adjuvant treatment.MethodsWe performed an ancillary analysis of GOG 49, 92, and 141, and included stage I patients who were surgically managed and received no neoadjuvant/adjuvant therapy. Multivariable Cox proportional hazards models were used to evaluate independent risk factors for recurrence by histology and to generate prognostic histology-specific nomograms for 3-year recurrence risk.ResultsWe identified 715 patients with SCC and 105 with AC; 20% with SCC and 17% with AC recurred. For SCC, lymphvascular space invasion (LVSI: HR 1.58, CI 1.12-2.22), tumor size (TS ≥4 cm: HR 2.67, CI 1.67-4.29), and depth of invasion (DOI; middle 1/3, HR 4.31, CI 1.81-10.26; deep 1/3, HR 7.05, CI 2.99-16.64) were associated with recurrence. For AC, only TS ≥4 cm, was associated with recurrence (HR 4.69, CI 1.25-17.63). For both histologies, there was an interaction effect between TS and LVSI. For those with SCC, DOI was most associated with recurrence (16% risk); for AC, TS conferred a 15% risk with negative LVSI versus a 25% risk with positive LVSI.ConclusionsCurrent treatment standards are based on the Sedlis criteria, specifically derived from data on SCC. However, risk factors for recurrence differ for squamous cell and adenocarcinoma of the cervix. Histology-specific nomograms accurately and linearly represent risk of recurrence for both SCC and AC tumors and may provide a more contemporary and tailored tool for clinicians to base adjuvant treatment recommendations to their patients with cervical cancer.

Published
2021

5. Carboplatin dosing in the treatment of ovarian cancer: An NRG oncology group study

Author

Praiss, Aaron M., Miller, Austin, Smith, Judith, Lichtman, Stuart M., Bookman, Michael, Aghajanian, Carol, Sabbatini, Paul, Backes, Floor, Cohn, David E., Argenta, Peter, Friedlander, Michael, Goodheart, Michael J., Mutch, David G., Gershenson, David M., Tewari, Krishnansu S., Wenham, Robert M., Wahner Hendrickson, Andrea E., Lee, Roger B., Gray, Heidi, Secord, Angeles Alvarez, Van Le, Linda, and O'Cearbhaill, Roisin E.

Published
2023
Full Text
View/download PDF

6. Circulating Tumor Cells In Advanced Cervical Cancer: NRG Oncology—Gynecologic Oncology Group Study 240 (NCT 00803062)

Author

Tewari, Krishnansu S, Sill, Michael W, Monk, Bradley J, Penson, Richard T, Moore, David H, Lankes, Heather A, Ramondetta, Lois M, Landrum, Lisa M, Randall, Leslie M, Oaknin, Ana, Leitao, Mario M, Eisenhauer, Eric L, DiSilvestro, Paul, Van Le, Linda, Pearl, Michael L, Burke, James J, Salani, Ritu, Richardson, Debra L, Michael, Helen E, Kindelberger, David W, and Birrer, Michael J

Subjects
Cervical Cancer, Clinical Research, Cancer, Adult, Aged, Antineoplastic Combined Chemotherapy Protocols, Biomarkers, Tumor, Disease Management, Female, Humans, Kaplan-Meier Estimate, Middle Aged, Molecular Targeted Therapy, Neoplastic Cells, Circulating, Prognosis, Treatment Outcome, Uterine Cervical Neoplasms, Oncology and Carcinogenesis, Pharmacology and Pharmaceutical Sciences, Oncology & Carcinogenesis
Abstract

To isolate circulating tumor cells (CTC) from women with advanced cervical cancer and estimate the impact of CTCs and treatment on overall survival and progression-free survival (PFS). A total of 7.5 mL of whole blood was drawn pre-cycle 1 and 36 days post-cycle 1 from patients enrolled on Gynecologic Oncology Group 0240, the phase III randomized trial that led directly to regulatory approval of the antiangiogenesis drug, bevacizumab, in women with recurrent/metastatic cervical cancer. CTCs (defined as anti-cytokeratin+/anti-CD45- cells) were isolated from the buffy coat layer using an anti-EpCAM antibody-conjugated ferrofluid and rare earth magnet, and counted using a semiautomated fluorescence microscope. The median pre-cycle 1 CTC count was 7 CTCs/7.5 mL whole blood (range, 0-18) and, at 36 days posttreatment, was 4 (range, 0-17). The greater the declination in CTCs between time points studied, the lower the risk of death [HR, 0.87; 95% confidence interval (CI), 0.79-0.95)]. Among patients with high (≥ median) pretreatment CTCs, bevacizumab treatment was associated with a reduction in the hazard of death (HR, 0.57; 95% CI, 0.32-1.03) and PFS (HR, 0.59; 95% CI, 0.36-0.96). This effect was not observed with low (< median) CTCs. CTCs can be isolated from women with advanced cervical cancer and may have prognostic significance. A survival benefit conferred by bevacizumab among patients with high pretreatment CTCs may reflect increased tumor neovascularization and concomitant vulnerability to VEGF inhibition. These data support studying CTC capture as a potential predictive biomarker.

Published
2020

7. Lifestyle intervention in ovarian cancer enhanced survival (LIVES) study (NRG/GOG0225): Recruitment, retention and baseline characteristics of a randomized trial of diet and physical activity in ovarian cancer survivors

Author

Thomson, Cynthia A., Crane, Tracy E., Miller, Austin, Gold, Michael A., Powell, Matthew, Bixel, Kristin, Van Le, Linda, DiSilvestro, Paul, Ratner, Elena, Lele, Shashikant, Guntupalli, Saketh, Huh, Warner, Robertson, Sharon E., Modesitt, Susan, Casey, A. Catherine, Basen-Engquist, Karen, Skiba, Meghan, Walker, Joan, Kachnic, Lisa, and Alberts, David S.

Published
2023
Full Text
View/download PDF

8. Randomized Trial of Intravenous Versus Intraperitoneal Chemotherapy Plus Bevacizumab in Advanced Ovarian Carcinoma: An NRG Oncology/Gynecologic Oncology Group Study.

Author

Walker, Joan, Brady, Mark, Fleming, Gini, Huang, Helen, DiSilvestro, Paul, Fujiwara, Keiichi, Alberts, David, Zheng, Wenxin, Cohn, David, Powell, Matthew, Van Le, Linda, Davidson, Susan, Gray, Heidi, Rose, Peter, Aghajanian, Carol, Myers, Tashanna, Alvarez Secord, Angeles, Rubin, Stephen, Mannel, Robert, Wenzel, Lari, and Tewari, Krishnansu

Subjects
Adult, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols, Bevacizumab, Carboplatin, Disease Progression, Drug Administration Schedule, Female, Humans, Infusions, Intravenous, Infusions, Parenteral, Middle Aged, Neoplasm Staging, Ovarian Neoplasms, Paclitaxel, Progression-Free Survival, Time Factors, United States
Abstract

PURPOSE: To evaluate the impact of two different intraperitoneal (IP) chemotherapy regimens on progression-free survival (PFS) among women with newly diagnosed advanced ovarian carcinoma. METHODS: Eligible patients were randomly assigned to six cycles of IV paclitaxel 80 mg/m2 once per week with intravenous (IV) carboplatin area under the curve 6 (IV carboplatin) versus IV paclitaxel 80 mg/m2 once per week with IP carboplatin area under the curve 6 (IP carboplatin) versus once every 3 weeks IV paclitaxel 135 mg/m2 over 3 hours day 1, IP cisplatin 75 mg/m2 day 2, and IP paclitaxel 60 mg/m2 day 8 (IP cisplatin). All participants received bevacizumab 15 mg/kg IV every 3 weeks in cycles 2 to 22. RESULTS: A total of 1,560 participants were enrolled and had 84.8 months of follow-up. The median PFS duration was 24.9 months in the IV carboplatin arm, 27.4 months in the IP carboplatin arm, and 26.2 months in the IP cisplatin arm. For the subgroup of 1,380 patients with stage II/III and residual disease of 1 cm or less, median PFS was 26.9 (IV-carboplatin), 28.7 (IP-carboplatin), and 27.8 months (IP cisplatin), respectively. Median PFS for patients with stage II/III and no residual disease was 35.9, 38.8, and 35.5 months, respectively. Median overall survival for all enrolled was 75.5, 78.9, and 72.9 months, respectively, and median overall survival for stage II/III with no gross residual disease was 98.8 months, 104.8 months, and not reached. Mean patient-reported Functional Assessment of Cancer Therapy neurotoxicity scores (Gynecologic Oncology Group) were similar for all arms, but the mean Trial Outcome Index of the Functional Assessment of Cancer Therapy-Ovary scores during chemotherapy were statistically worse in the IP cisplatin arm. CONCLUSION: Compared with the IV carboplatin reference arm, the duration of PFS was not significantly increased with either IP regimen when combined with bevacizumab and was better tolerated than IP cisplatin.

Published
2019

9. Nomogram for Predicting Individual Survival After Recurrence of Advanced-Stage, High-Grade Ovarian Carcinoma.

Author

Rose, Peter G, Java, James J, Salani, Ritu, Geller, Melissa A, Secord, Angeles Alvarez, Tewari, Krishnansu S, Bender, David P, Mutch, David G, Friedlander, Michael L, Van Le, Linda, Method, Michael W, Hamilton, Chad A, Lee, Roger B, Wenham, Robert M, Guntupalli, Saketh R, Markman, Maurie, Muggia, Franco M, Armstrong, Deborah K, Bookman, Michael A, Burger, Robert A, and Copeland, Larry J

Subjects
Reproductive Medicine, Biomedical and Clinical Sciences, Clinical Sciences, Oncology and Carcinogenesis, Cancer, Ovarian Cancer, Clinical Research, Rare Diseases, Aged, Antineoplastic Agents, Phytogenic, Carcinoma, Female, Humans, Middle Aged, Neoplasm Recurrence, Local, Nomograms, Ovarian Neoplasms, Paclitaxel, Platinum Compounds, Retrospective Studies, United States, Paediatrics and Reproductive Medicine, Obstetrics & Reproductive Medicine, Reproductive medicine
Abstract

ObjectiveTo analyze clinical prognostic factors for survival after recurrence of high-grade, advanced-stage ovarian-peritoneal-tubal carcinoma and to develop a nomogram to predict individual survival after recurrence.MethodsWe retrospectively analyzed patients treated in multicenter Gynecologic Oncology Group protocols for stage III and IV ovarian-peritoneal-tubal carcinoma who underwent primary debulking surgery, received chemotherapy with paclitaxel and a platinum compound, and subsequently developed recurrence. Prognostic factors affecting survival were identified and used to develop a nomogram, which was both internally and externally validated.ResultsThere were 4,739 patients included in this analysis, of whom, 84% had stage III and 16% had stage IV ovarian carcinoma. At a median follow-up of 88.8 months (95% CI 86.2-92.0 months), the vast majority of patients (89.4%) had died. The median survival after recurrence was 21.4 months (95% CI 20.5-21.9 months). Time to recurrence after initial chemotherapy, clear cell or mucinous histology, performance status, stage IV disease, and age were significant variables used to develop a nomogram for survival after recurrence, which had a concordance index of 0.67. The time to recurrence alone accounted for 85% of the prognostic information. Similar results were found for patients who underwent second look laparotomy and had a complete pathologic response or received intraperitoneal chemotherapy.ConclusionFor individuals with advanced-stage ovarian carcinoma who recur after standard first-line therapy, estimated survivals after recurrence are closely related to the time to recurrence after chemotherapy and prognostic variables can be used to predict subsequent survival.Clinical trial registrationClinialTrials.gov, NCT00002568, NCT00837993, NCT00002717, NCT01074398, and NCT00011986.

Published
2019

10. Predictive modeling for determination of microscopic residual disease at primary cytoreduction: An NRG Oncology/Gynecologic Oncology Group 182 Study.

Author

Horowitz, Neil, Larry Maxwell, G, Miller, Austin, Hamilton, Chad, Rungruang, Bunja, Rodriguez, Noah, Richard, Scott, Krivak, Thomas, Fowler, Jeffrey, Mutch, David, Van Le, Linda, Lee, Roger, Argenta, Peter, Bender, David, Gershenson, David, Java, James, Bookman, Michael, and Tewari, Krishnansu

Subjects
Microscopic residual, Ovarian cancer, Aged, CA-125 Antigen, Carcinoma, Ovarian Epithelial, Cohort Studies, Cytoreduction Surgical Procedures, Female, Humans, Membrane Proteins, Middle Aged, Models, Statistical, Neoplasm Staging, Neoplasm, Residual, Neoplasms, Glandular and Epithelial, Ovarian Neoplasms, Predictive Value of Tests, Randomized Controlled Trials as Topic, Regression Analysis
Abstract

OBJECTIVE: Microscopic residual disease following complete cytoreduction (R0) is associated with a significant survival benefit for patients with advanced epithelial ovarian cancer (EOC). Our objective was to develop a prediction model for R0 to support surgeons in their clinical care decisions. METHODS: Demographic, pathologic, surgical, and CA125 data were collected from GOG 182 records. Patients enrolled prior to September 1, 2003 were used for the training model while those enrolled after constituted the validation data set. Univariate analysis was performed to identify significant predictors of R0 and these variables were subsequently analyzed using multivariable regression. The regression model was reduced using backward selection and predictive accuracy was quantified using area under the receiver operating characteristic area under the curve (AUC) in both the training and the validation data sets. RESULTS: Of the 3882 patients enrolled in GOG 182, 1480 had complete clinical data available for the analysis. The training data set consisted of 1007 patients (234 with R0) while the validation set was comprised of 473 patients (122 with R0). The reduced multivariable regression model demonstrated several variables predictive of R0 at cytoreduction: Disease Score (DS) (p

Published
2018

11. Genome-wide association study evaluating single-nucleotide polymorphisms and outcomes in patients with advanced stage serous ovarian or primary peritoneal cancer: An NRG Oncology/Gynecologic Oncology Group study.

Author

Moore, Kathleen, Tritchler, David, Kaufman, Kenneth, Lankes, Heather, Quinn, Michael, Van Le, Linda, Berchuck, Andrew, Backes, Floor, Lee, Roger, Kesterson, Joshua, Wenham, Robert, Armstrong, Deborah, Krivak, Thomas, Bookman, Michael, Birrer, Michael, and Tewari, Krishnansu

Subjects
Advanced stage serous ovarian, Genome-wide association, Primary peritoneal cancer, Adult, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols, Cystadenocarcinoma, Serous, Female, Genome-Wide Association Study, Humans, Middle Aged, Neoplasm Staging, Ovarian Neoplasms, Peritoneal Neoplasms, Polymorphism, Single Nucleotide, Prognosis, Randomized Controlled Trials as Topic
Abstract

OBJECTIVE: This study evaluated single nucleotide polymorphisms (SNPs) associated with progression free (PFS) and overall survival (OS) in patients with advanced stage serous EOC. METHODS: Patients enrolled in GOG-172 and 182 who provided specimens for translational research and consent were included. Germline DNA was evaluated with the Illuminas HumanOMNI1-Quad beadchips and scanned using Illuminas iScan optical imaging system. SNPs with allele frequency>0.05 and genotyping rate>0.98 were included. Analysis of SNPs for PFS and OS was done using Cox regression. Statistical significance was determined using Bonferroni corrected p-values with genomic control adjustment. RESULTS: The initial GWAS analysis included 1,124,677 markers in 396 patients. To obtain the final data set, quality control checks were performed and limited to serous tumors and self-identified Caucasian race. In total 636,555 SNPs and 289 patients passed all the filters. The pre-specified statistical level of significance was 7.855e-08. No SNPs met this criteria for PFS or OS, however, two SNPs were close to significance (rs10899426 p-2.144e-08) (rs6256 p-9.774e-07) for PFS and 2 different SNPs were identified (rs295315 p-7.536e-07; rs17693104 p-7.734e-07) which were close to significance for OS. CONCLUSIONS: Using the pre-specified level of significance of 1×10-08, we did not identify any SNPs of statistical significance for OS or PFS, however several were close. The SNPs identified in this GWAS study will require validation and these preliminary findings may lead to identification of novel pathways and biomarkers.

Published
2017

14. Trebananib or placebo plus carboplatin and paclitaxel as first-line treatment for advanced ovarian cancer (TRINOVA-3/ENGOT-ov2/GOG-3001): a randomised, double-blind, phase 3 trial

Author

Vergote, Ignace, Scambia, Giovanni, Park, Sang Yoon, Song, Yong Sang, Makarova, Yulia, Trinidad, Joshua, Ngan, Hextan Yuen Sheung, Bamias, Aristotelis, Aravantinos, Gerasimos, Nam, Joo-Hyun, Gorbunova, Vera, Krikunova, Ludmila, Bae, Duk-Soo, Arija, Jose Angel Arranz, Mirza, Mansoor Raza, Zamagni, Claudio, Papandreou, Christos, Raspagliesi, Francesco, Lisyanskaya, Alla, Benzaquen, Ana Oaknin, Tognon, Germana, Ortega, Eugenia, Herraez, Antonio Casado, Buscema, Joseph, Green, Andrew, Burger, Robert, Sakaeva, Dina, Sanchez, Andres Redondo, Ghamande, Sharad, King, Laurel, Petru, Edgar, Peen, Ulla, Takeuchi, Satoshi, Ushijima, Kimio, Martin, Antonio Gonzalez, Kamelle, Scott, Carney, Michael, Marth, Christian, Forget, Frédéric, Bentley, James, Sehouli, Jalid, Colombo, Nicoletta, Zola, Paolo, Kato, Hidenori, Fadeeva, Natalya, Gotovkin, Evgeny, Vladimirov, Vladimir, Marin, Margarita Romeo, Alia, Eva Guerra, Shahin, Mark, Bhoola, Snehalkumar, Tewari, Krishnansu, Anderson, Daniel, Honhon, Brigitte, Pelgrims, Joseph (Gino), Oza, Amit, Jimenez, Jesus Garcia-Donas, Hansen, Vincent, O'Malley, David, Benjamin, Ivor, Renard, Vincent, Van den Bulck, Heidi, Meier, Werner, Haenle, Claudia, Koumakis, Georgios, Yokota, Harushige, Popov, Vadim, Bradley, William, Wenham, Robert, Reid, Robert, McNamara, Donna, Friedman, Richard, Barlin, Joyce, Spirtos, Nicola, Chapman, Julia, Sevelda, Paul, Huizing, Manon, Lamot, Caroline, Goffin, Frédéric, Hondt, Lionel D, Covens, Allan, Spadafora, Silvana, Rautenberg, Beate, Reimer, Toralf, Möbus, Volker, Hilpert, Felix, Gropp-Meier, Martina, Savarese, Antonella, Pignata, Sandro, Verderame, Francesco, Mizuno, Mika, Takano, Hirokuni, Ottevanger, Petronella, Velasco, Andres Poveda, Palacio-Vazquez, Isabel, Law, Amy, McIntyre, Kristi, Teneriello, Michael, Fields, Abbie, Lentz, Samuel, Street, Daron, Schwartz, Benjamin, Mannel, Robert, Lim, Peter, Pulaski, Heather, Janni, Wolfgang, Zorr, Andreas, Karck, Ulrich, Cheng, Ashley Chi Kin, Sorio, Roberto, Gridelli, Cesare, Aoki, Daisuke, Oishi, Tetsuro, Hirashima, Yasuyuki, Boere, Ingrid, Ferrer, Esther Falco, Braly, Patricia, Wilks, Sharon, Lee, Christine, Schilder, Jeanne, Veljovich, Dan, Secord, Angeles, Davis, Kevin, Rojas-Espaillat, Luis, Lele, Shashikant, DePasquale, Stephen, Squatrito, Robert, Schauer, Christian, Dirix, Luc, Vuylsteke, Peter, Joosens, Eric, Provencher, Diane, Lueck, Hans-Joachim, Hein, Alexander, Burges, Alexander, Canzler, Ulrich, Park-Simon, Tjoung-Won, Griesinger, Frank, Gadducci, Angiolo, Alabiso, Oscar, Okamoto, Aikou, Sawasaki, Takashi, Saito, Toshiaki, Ibañez, Ana Herrero, Calomeni, Coralia, Spillman, Monique, Choksi, Janak, Taylor, Nicholas, Muller, Carolyn, Moore, David, DiSilvestro, Paul, Cunningham, Mary, Rose, Peter, Oppelt, Peter, Verhoeven, Didier, Graas, Marie-Pascale, Ghatage, Prafull, Tonkin, Katia, Kurzeder, Christian, Schnappauf, Benjamin, Müller, Volkmar, Schmalzrie, Hannah, Kalofonos, Haralambos, Bruzzone, Milena, Kroep, Judith, Diaz, Cristina Caballero, Garcia, Jeronimo Martinez, Polo, Susana Hernando, Garrison, Mitchell, Rocconi, Rodney, Andrews, Stephen, Bristow, Robert, McHale, Michael, Basil, Jack, Houck III, William, Bell, Maria, Cosin, Jonathan, Modesitt, Susan, Kendrick, James, Wade III, James, Wong, Cheung, Evans, Anthony, Buekers, Thomas, Vanderkwaak, Timothy, Ferriss, James, Darus, Christopher, DAndre, Stacy, Higgins, Robert, Monk, Bradley, Bakkum-Gamez, Jamie, DeMars, Leslie, Van Le, Linda, Puls, Larry, Trehan, Shruti, LaPolla, James, Michelson, Elizabeth Dickson, Merchant, Joseph, Peterson, Christopher, Reid, Gary, Seago, Donald, Zweizig, Susan, Gajewski, Walter, Panwalkar, Amit, Leikermoser, Rudolf, Bogner, Gerhard, Debruyne, Philip, D'hondt, Randal, Berteloot, Patrick, Kerger, Joseph, Biagi, James, Castonguay, Vincent, Welch, Stephen, Muhic, Aida, Heubner, Martin, Grischke, Eva-Maria, Rack, Brigitte, Fleisch, Markus, Lordick, Florian, Pectasides, Dimitrios, Ho, Wing Ming, Selvaggi, Luigi, Vasquez, Flavia Morales, Villanueva, William Orlando Brito, Alavez, Alejandro Molina, Kessels, Lonneke, Bertran, Ana Santaballa, Fernandez, Cesar Mendiola, Fabregat, Miguel Beltran, Del Prete, Salvatore, Elkas, John, Cecchi, Gary, Kumar, Pallavi, Huh, Warner, Messing, Mark, Karimi, Misagh, Kelley, Ann, Edraki, Babak, Mutch, David, Leiserowitz, Gary, Anderson, Jeanne, Lentz, Scott, Chambers, Setsuko, Morris, Robert, Waggoner, Steven, Gordon, Alan, Method, Michael, Johnson, Peter, Lord, Raymond, Drake, Janet, Sivarajan, Kulumani, Midathada, Madhu, Rice, Kristen, Wadsworth, Troy, Pavelka, James, Edwards, Robert, Miller, David Scott, Ford, Patricia Locantore, Hurteau, Jean, Bender, David, Schimp, Veronica, Creasman, William, Lerner, Rachel, Chamberlain, Donald, Kueck, Angela, McDonald, John, Malad, Salman, Robinson-Bennett, Bernice, Davidson, Susan, Krivak, Thomas, Lestingi, Timothy, Arango, Hector, Berard, Paul, Finkelstein, Karen, Gaur, Rakesh, Krasner, Carolyn, Ueland, Frederick, Talmage, Lance, Yamada, Seiko, Sutton, Gregory, Potkul, Ronald, Prasad-Hayes, Monica, Osborne, Janet, Celano, Paul, Thigpen, James, Sharma, Sudarshan, Schilder, Russell, Tammela, Jonathan, Kemeny, Mary, Brown, Amy, Eisenhauer, Eric, Williams, James, Rowland, Kendrith, Nahum, Kenneth, Burke, James, Dar, Zahid, Fleming, Nicole, Gibb, Randall, Guirguis, Alfred, Herzog, Thomas, John, Veena, Kumar, Santhosh, Kamat, Aparna, Kassar, Mohamad, Leitao, Mario, Levine, Lyuba, Mendez, Luis, Patel, Dhimant, Berry, Emily, Warshal, David, Wolf, Judith, Zarwan, Corrine, Collins, Yvonne, Spitzer, Gary, Miller, Brigitte, Einstein, Mark, O'Malley, David M, Van Calster, Ben, Park, Sang-Yoon, del Campo, Josep M, Wenham, Robert M, Covens, Al, Raza Mirza, Mansoor, Kroep, Judith R, Ma, Haijun, Pickett, Cheryl A, and Monk, Bradley J

Published
2019
Full Text
View/download PDF

15. Pathologic findings at risk-reducing salpingo-oophorectomy: primary results from Gynecologic Oncology Group Trial GOG-0199.

Author

Sherman, Mark, Piedmonte, Marion, Mai, Phuong, Ioffe, Olga, Ronnett, Brigitte, Van Le, Linda, Ivanov, Iouri, Bell, Maria, Blank, Stephanie, DiSilvestro, Paul, Hamilton, Chad, Wakeley, Katie, Kauff, Noah, Yamada, S, Rodriguez, Gustavo, Skates, Steven, Alberts, David, Walker, Joan, Minasian, Lori, Lu, Karen, Greene, Mark, and Tewari, Krishnansu

Subjects
Adult, Biomarkers, Tumor, Breast Neoplasms, CA-125 Antigen, Fallopian Tube Neoplasms, Female, Genes, BRCA1, Genes, BRCA2, Genetic Predisposition to Disease, Humans, Middle Aged, Mutation, Neoplasm Invasiveness, Neoplasms, Unknown Primary, Ovarian Neoplasms, Ovariectomy, Risk Factors
Abstract

PURPOSE: Risk-reducing salpingo-oophorectomy (RRSO) lowers mortality from ovarian/tubal and breast cancers among BRCA1/2 mutation carriers. Uncertainties persist regarding potential benefits of RRSO among high-risk noncarriers, optimal surgical age, and anatomic origin of clinically occult cancers detected at surgery. To address these topics, we analyzed surgical treatment arm results from Gynecologic Oncology Group Protocol-0199 (GOG-0199), the National Ovarian Cancer Prevention and Early Detection Study. PARTICIPANTS AND METHODS: This analysis included asymptomatic high-risk women age ≥ 30 years who elected RRSO at enrollment. Women provided risk factor data and underwent preoperative cancer antigen 125 (CA-125) serum testing and transvaginal ultrasound (TVU). RRSO specimens were processed according to a standardized tissue processing protocol and underwent central pathology panel review. Research-based BRCA1/2 mutation testing was performed when a participants mutation status was unknown at enrollment. Relationships between participant characteristics and diagnostic findings were assessed using univariable statistics and multivariable logistic regression. RESULTS: Invasive or intraepithelial ovarian/tubal/peritoneal neoplasms were detected in 25 (2.6%) of 966 RRSOs (BRCA1 mutation carriers, 4.6%; BRCA2 carriers, 3.5%; and noncarriers, 0.5%; P < .001). In multivariable models, positive BRCA1/2 mutation status (P = .0056), postmenopausal status (P = .0023), and abnormal CA-125 levels and/or TVU examinations (P < .001) were associated with detection of clinically occult neoplasms at RRSO. For 387 women with negative BRCA1/2 mutation testing and normal CA-125 levels, findings at RRSO were benign. CONCLUSION: Clinically occult cancer was detected among 2.6% of high-risk women undergoing RRSO. BRCA1/2 mutation, postmenopausal status, and abnormal preoperative CA-125 and/or TVU were associated with cancer detection at RRSO. These data can inform management decisions among women at high risk of ovarian/tubal cancer.

Published
2014

16. The effect of older age on treatment outcomes in women with advanced ovarian cancer receiving chemotherapy: An NRG-Oncology/Gynecologic Oncology Group (GOG-0182-ICON5) ancillary study

Author

Sia, Tiffany Y., primary, Tew, William P., additional, Purdy, Christopher, additional, Chi, Dennis S., additional, Menzin, Andrew W., additional, Lovecchio, John L., additional, Bookman, Michael A., additional, Cohn, David E., additional, Teoh, Deanna G., additional, Friedlander, Michael, additional, Bender, David, additional, Mutch, David G., additional, Gershenson, David M., additional, Tewari, Krishnansu S., additional, Wenham, Robert M., additional, Wahner Hendrickson, Andrea E., additional, Lee, Roger B., additional, Gray, Heidi J., additional, Secord, Angeles Alvarez, additional, Van Le, Linda, additional, and Lichtman, Stuart M., additional

Published
2023
Full Text
View/download PDF

17. Supplementary Data from Circulating Tumor Cells In Advanced Cervical Cancer: NRG Oncology—Gynecologic Oncology Group Study 240 (NCT 00803062)

Author

Tewari, Krishnansu S., primary, Sill, Michael W., primary, Monk, Bradley J., primary, Penson, Richard T., primary, Moore, David H., primary, Lankes, Heather A., primary, Ramondetta, Lois M., primary, Landrum, Lisa M., primary, Randall, Leslie M., primary, Oaknin, Ana, primary, Leitao, Mario M., primary, Eisenhauer, Eric L., primary, DiSilvestro, Paul, primary, Van Le, Linda, primary, Pearl, Michael L., primary, Burke, James J., primary, Salani, Ritu, primary, Richardson, Debra L., primary, Michael, Helen E., primary, Kindelberger, David W., primary, and Birrer, Michael J., primary

Published
2023
Full Text
View/download PDF

20. Randomized Clinical Trial of Intravenous Versus Intraperitoneal Chemotherapy Plus Bevacizumab in Advanced Ovarian Carcinoma: An NRG Oncology/Gynecologic Oncology Group Study

Author

Walker, Joan L., Brady, Mark F., Wenzel, Lari, Fleming, Gini F., Huang, Helen Q., DiSilvestro, Paul A., Fujiwara, Keiichi, Alberts, David S., Zheng, Wenxin, Tewari, Krishnansu S., Cohn, David E., Powell, Matthew A., Van Le, Linda, Davidson, Susan A., Gray, Heidi J., Rose, Peter G., Aghajanian, Carol, Myers, Tashanna, Secord, Angeles Alvarez, Rubin, Stephen C., and Mannel, Robert S.

Published
2019
Full Text
View/download PDF

26. Technetium Tc 99m sulfur colloid phenotypic probe for the pharmacokinetics and pharmacodynamics of PEGylated liposomal doxorubicin in women with ovarian cancer

Author

Giovinazzo, Hugh, Kumar, Parag, Sheikh, Arif, Brooks, Kristina M., Ivanovic, Marija, Walsh, Mark, Caron, Whitney P., Kowalsky, Richard J., Song, Gina, Whitlow, Ann, Clarke-Pearson, Daniel L., Brewster, Wendy R., Van Le, Linda, Zamboni, Beth A., Bae-Jump, Victoria, Gehrig, Paola A., and Zamboni, William C.

Published
2016
Full Text
View/download PDF

31. Is bilateral lymphadenectomy for midline squamous carcinoma of the vulva always necessary? An analysis from Gynecologic Oncology Group (GOG) 173

Author

Coleman, Robert L., Ali, Shamshad, Levenback, Charles F., Gold, Michael A., Fowler, Jeffrey M., Judson, Patricia L., Bell, Maria C., De Geest, Koen, Spirtos, Nick M., Potkul, Ronald K., Leitao, Mario M., Jr., Bakkum-Gamez, Jamie N., Rossi, Emma C., Lentz, Samuel S., Burke, James J., II, Van Le, Linda, and Trimble, Cornelia L.

Published
2013
Full Text
View/download PDF

40. Radiotherapy Versus Inguinofemoral Lymphadenectomy as Treatment for Vulvar Cancer Patients With Micrometastases in the Sentinel Node : Results of GROINSS-V II

Author

Oonk, Maaike H. M., Slomovitz, Brian, Baldwin, Peter J. W., van Doorn, Helena C., van der Velden, Jacobus, de Hullu, Joanne A., Gaarenstroom, Katja N., Slangen, Brigitte F. M., Vergote, Ignace, Brannstrom, Mats, van Dorst, Eleonora B. L., van Driel, Willemien J., Hermans, Ralph H., Nunns, David, Widschwendter, Martin, Nugent, David, Holland, Cathrine M., Sharma, Aarti, DiSilvestro, Paul A., Mannel, Robert, Boll, Dorry, Cibula, David, Covens, Al, Provencher, Diane, Runnebaum, Ingo B., Luesley, David, Ellis, Patricia, Duncan, Timothy J., Tjiong, Ming Y., Cruickshank, Derek J., Kjolhede, Preben, Levenback, Charles F., Bouda, Jiri, Kieser, Katharina E., Palle, Connie, Spirtos, Nicola M., O'Malley, David M., Leitao, Mario M., Geller, Melissa A., Dhar, Kalyan, Asher, Viren, Tamussino, Karl, Tobias, Daniel H., Borgfeldt, Christer, Lea, Jayanthi S., Bailey, Jo, Lood, Margareta, Eyjolfsdottir, Brynhildur, Attard-Montalto, Stephen, Tewari, Krishnansu S., Manchanda, Ranjit, Jensen, Pernille T., Persson, Pär, Van Le, Linda, Putter, Hein, de Bock, Geertruida H., Monk, Bradley J., Creutzberg, Carien L., van der Zee, Ate G. J., Oonk, Maaike H. M., Slomovitz, Brian, Baldwin, Peter J. W., van Doorn, Helena C., van der Velden, Jacobus, de Hullu, Joanne A., Gaarenstroom, Katja N., Slangen, Brigitte F. M., Vergote, Ignace, Brannstrom, Mats, van Dorst, Eleonora B. L., van Driel, Willemien J., Hermans, Ralph H., Nunns, David, Widschwendter, Martin, Nugent, David, Holland, Cathrine M., Sharma, Aarti, DiSilvestro, Paul A., Mannel, Robert, Boll, Dorry, Cibula, David, Covens, Al, Provencher, Diane, Runnebaum, Ingo B., Luesley, David, Ellis, Patricia, Duncan, Timothy J., Tjiong, Ming Y., Cruickshank, Derek J., Kjolhede, Preben, Levenback, Charles F., Bouda, Jiri, Kieser, Katharina E., Palle, Connie, Spirtos, Nicola M., O'Malley, David M., Leitao, Mario M., Geller, Melissa A., Dhar, Kalyan, Asher, Viren, Tamussino, Karl, Tobias, Daniel H., Borgfeldt, Christer, Lea, Jayanthi S., Bailey, Jo, Lood, Margareta, Eyjolfsdottir, Brynhildur, Attard-Montalto, Stephen, Tewari, Krishnansu S., Manchanda, Ranjit, Jensen, Pernille T., Persson, Pär, Van Le, Linda, Putter, Hein, de Bock, Geertruida H., Monk, Bradley J., Creutzberg, Carien L., and van der Zee, Ate G. J.

Abstract

PURPOSE The Groningen International Study on Sentinel nodes in Vulvar cancer (GROINSS-V)-II investigated whether inguinofemoral radiotherapy is a safe alternative to inguinofemoral lymphadenectomy (IFL) in vulvar cancer patients with a metastatic sentinel node (SN). METHODS GROINSS-V-II was a prospective multicenter phase-II single-arm treatment trial, including patients with early-stage vulvar cancer (diameter < 4 cm) without signs of lymph node involvement at imaging, who had primary surgical treatment (local excision with SN biopsy). Where the SN was involved (metastasis of any size), inguinofemoral radiotherapy was given (50 Gy). The primary end point was isolated groin recurrence rate at 24 months. Stopping rules were defined for the occurrence of groin recurrences. RESULTS From December 2005 until October 2016, 1,535 eligible patients were registered. The SN showed metastasis in 322 (21.0%) patients. In June 2010, with 91 SN-positive patients included, the stopping rule was activated because the isolated groin recurrence rate in this group went above our predefined threshold. Among 10 patients with an isolated groin recurrence, nine had SN metastases > 2 mm and/or extracapsular spread. The protocol was amended so that those with SN macrometastases (> 2 mm) underwent standard of care (IFL), whereas patients with SN micrometastases (<= 2 mm) continued to receive inguinofemoral radiotherapy. Among 160 patients with SN micrometastases, 126 received inguinofemoral radiotherapy, with an ipsilateral isolated groin recurrence rate at 2 years of 1.6%. Among 162 patients with SN macrometastases, the isolated groin recurrence rate at 2 years was 22% in those who underwent radiotherapy, and 6.9% in those who underwent IFL (P = .011). Treatment-related morbidity after radiotherapy was less frequent compared with IFL. CONCLUSION Inguinofemoral radiotherapy is a safe alternative for IFL in patients with SN micrometastases, with minimal morbidity. For patients wit

Published
2021
Full Text
View/download PDF

41. Radiotherapy Versus Inguinofemoral Lymphadenectomy as Treatment for Vulvar Cancer Patients With Micrometastases in the Sentinel Node:Results of GROINSS-V II

Author

Oonk, Maaike H.M., Slomovitz, Brian, Baldwin, Peter J.W., van Doorn, Helena C., van der Velden, Jacobus, de Hullu, Joanne A., Gaarenstroom, Katja N., Slangen, Brigitte F.M., Vergote, Ignace, Brännström, Mats, van Dorst, Eleonora B.L., van Driel, Willemien J., Hermans, Ralph H., Nunns, David, Widschwendter, Martin, Nugent, David, Holland, Cathrine M., Sharma, Aarti, DiSilvestro, Paul A., Mannel, Robert, Boll, Dorry, Cibula, David, Covens, Al, Provencher, Diane, Runnebaum, Ingo B., Luesley, David, Ellis, Patricia, Duncan, Timothy J., Tjiong, Ming Y., Cruickshank, Derek J., Kjølhede, Preben, Levenback, Charles F., Bouda, Jiri, Kieser, Katharina E., Palle, Connie, Spirtos, Nicola M., O'Malley, David M., Leitao, Mario M., Geller, Melissa A., Dhar, Kalyan, Asher, Viren, Tamussino, Karl, Tobias, Daniel H., Borgfeldt, Christer, Lea, Jayanthi S., Bailey, Jo, Lood, Margareta, Eyjolfsdottir, Brynhildur, Attard-Montalto, Stephen, Tewari, Krishnansu S., Manchanda, Ranjit, Jensen, Pernille T., Persson, Par, Van Le, Linda, Putter, Hein, de Bock, Geertruida H., Monk, Bradley J., Creutzberg, Carien L., van der Zee, Ate G.J., Oonk, Maaike H.M., Slomovitz, Brian, Baldwin, Peter J.W., van Doorn, Helena C., van der Velden, Jacobus, de Hullu, Joanne A., Gaarenstroom, Katja N., Slangen, Brigitte F.M., Vergote, Ignace, Brännström, Mats, van Dorst, Eleonora B.L., van Driel, Willemien J., Hermans, Ralph H., Nunns, David, Widschwendter, Martin, Nugent, David, Holland, Cathrine M., Sharma, Aarti, DiSilvestro, Paul A., Mannel, Robert, Boll, Dorry, Cibula, David, Covens, Al, Provencher, Diane, Runnebaum, Ingo B., Luesley, David, Ellis, Patricia, Duncan, Timothy J., Tjiong, Ming Y., Cruickshank, Derek J., Kjølhede, Preben, Levenback, Charles F., Bouda, Jiri, Kieser, Katharina E., Palle, Connie, Spirtos, Nicola M., O'Malley, David M., Leitao, Mario M., Geller, Melissa A., Dhar, Kalyan, Asher, Viren, Tamussino, Karl, Tobias, Daniel H., Borgfeldt, Christer, Lea, Jayanthi S., Bailey, Jo, Lood, Margareta, Eyjolfsdottir, Brynhildur, Attard-Montalto, Stephen, Tewari, Krishnansu S., Manchanda, Ranjit, Jensen, Pernille T., Persson, Par, Van Le, Linda, Putter, Hein, de Bock, Geertruida H., Monk, Bradley J., Creutzberg, Carien L., and van der Zee, Ate G.J.

Abstract

PURPOSE: The Groningen International Study on Sentinel nodes in Vulvar cancer (GROINSS-V)-II investigated whether inguinofemoral radiotherapy is a safe alternative to inguinofemoral lymphadenectomy (IFL) in vulvar cancer patients with a metastatic sentinel node (SN). METHODS: GROINSS-V-II was a prospective multicenter phase-II single-arm treatment trial, including patients with early-stage vulvar cancer (diameter < 4 cm) without signs of lymph node involvement at imaging, who had primary surgical treatment (local excision with SN biopsy). Where the SN was involved (metastasis of any size), inguinofemoral radiotherapy was given (50 Gy). The primary end point was isolated groin recurrence rate at 24 months. Stopping rules were defined for the occurrence of groin recurrences. RESULTS: From December 2005 until October 2016, 1,535 eligible patients were registered. The SN showed metastasis in 322 (21.0%) patients. In June 2010, with 91 SN-positive patients included, the stopping rule was activated because the isolated groin recurrence rate in this group went above our predefined threshold. Among 10 patients with an isolated groin recurrence, nine had SN metastases > 2 mm and/or extracapsular spread. The protocol was amended so that those with SN macrometastases (> 2 mm) underwent standard of care (IFL), whereas patients with SN micrometastases (≤ 2 mm) continued to receive inguinofemoral radiotherapy. Among 160 patients with SN micrometastases, 126 received inguinofemoral radiotherapy, with an ipsilateral isolated groin recurrence rate at 2 years of 1.6%. Among 162 patients with SN macrometastases, the isolated groin recurrence rate at 2 years was 22% in those who underwent radiotherapy, and 6.9% in those who underwent IFL (P = .011). Treatment-related morbidity after radiotherapy was less frequent compared with IFL. CONCLUSION: Inguinofemoral radiotherapy is a safe alternative for IFL in patients with SN micrometastases, with minimal morbidity. For patients

Published
2021

44. Integrated genomic characterization of endometrial carcinoma

Author

Getz, Gad, Gabriel, Stacey B., Cibulskis, Kristian, Lander, Eric, Sivachenko, Andrey, Sougnez, Carrie, Lawrence, Mike, Kandoth, Cyriac, Dooling, David, Fulton, Robert, Fulton, Lucinda, Kalicki-Veizer, Joelle, McLellan, Michael D., OʼLaughlin, Michelle, Schmidt, Heather, Wilson, Richard K., Ye, Kai, Ding, Li, Mardis, Elaine R., Ally, Adrian, Balasundaram, Miruna, Birol, Inanc, Butterfield, Yaron S. N., Carlsen, Rebecca, Carter, Candace, Chu, Andy, Chuah, Eric, Chun, Hye-Jung E., Dhalla, Noreen, Guin, Ranabir, Hirst, Carrie, Holt, Robert A., Jones, Steven J. M., Lee, Darlene, Li, Haiyan I., Marra, Marco A., Mayo, Michael, Moore, Richard A., Mungall, Andrew J., Plettner, Patrick, Schein, Jacqueline E., Sipahimalani, Payal, Tam, Angela, Varhol, Richard J., Gordon Robertson, A., Cherniack, Andrew D., Pashtan, Itai, Saksena, Gordon, Onofrio, Robert C., Schumacher, Steven E., Tabak, Barbara, Carter, Scott L., Hernandez, Bryan, Gentry, Jeff, Salvesen, Helga B., Ardlie, Kristin, Winckler, Wendy, Beroukhim, Rameen, Meyerson, Matthew, Hadjipanayis, Angela, Lee, Semin, Mahadeshwar, Harshad S., Park, Peter, Protopopov, Alexei, Ren, Xiaojia, Seth, Sahil, Song, Xingzhi, Tang, Jiabin, Xi, Ruibin, Yang, Lixing, Zeng, Dong, Kucherlapati, Raju, Chin, Lynda, Zhang, Jianhua, Todd Auman, J., Balu, Saianand, Bodenheimer, Tom, Buda, Elizabeth, Neil Hayes, D., Hoyle, Alan P., Jefferys, Stuart R., Jones, Corbin D., Meng, Shaowu, Mieczkowski, Piotr A., Mose, Lisle E., Parker, Joel S., Perou, Charles M., Roach, Jeff, Shi, Yan, Simons, Janae V., Soloway, Mathew G., Tan, Donghui, Topal, Michael D., Waring, Scot, Wu, Junyuan, Hoadley, Katherine A., Baylin, Stephen B., Bootwalla, Moiz S., Lai, Phillip H., Triche, Timothy J., Jr, Van Den Berg, David J., Weisenberger, Daniel J., Laird, Peter W., Shen, Hui, Cho, Juok, DiCara, Daniel, Frazer, Scott, Heiman, David, Jing, Rui, Lin, Pei, Mallard, Will, Stojanov, Petar, Voet, Doug, Zhang, Hailei, Zou, Lihua, Noble, Michael, Reynolds, Sheila M., Shmulevich, Ilya, Arman Aksoy, B., Antipin, Yevgeniy, Ciriello, Giovanni, Dresdner, Gideon, Gao, Jianjiong, Gross, Benjamin, Jacobsen, Anders, Ladanyi, Marc, Reva, Boris, Sander, Chris, Sinha, Rileen, Onur Sumer, S., Taylor, Barry S., Cerami, Ethan, Weinhold, Nils, Schultz, Nikolaus, Shen, Ronglai, Benz, Stephen, Goldstein, Ted, Haussler, David, Ng, Sam, Szeto, Christopher, Stuart, Joshua, Benz, Christopher C., Yau, Christina, Zhang, Wei, Annala, Matti, Broom, Bradley M., Casasent, Tod D., Ju, Zhenlin, Liang, Han, Liu, Guoyan, Lu, Yiling, Unruh, Anna K., Wakefield, Chris, Weinstein, John N., Zhang, Nianxiang, Liu, Yuexin, Broaddus, Russell, Akbani, Rehan, Mills, Gordon B., Adams, Christopher, Barr, Thomas, Black, Aaron D., Bowen, Jay, Deardurff, John, Frick, Jessica, Gastier-Foster, Julie M., Grossman, Thomas, Harper, Hollie A., Hart-Kothari, Melissa, Helsel, Carmen, Hobensack, Aaron, Kuck, Harkness, Kneile, Kelley, Leraas, Kristen M., Lichtenberg, Tara M., McAllister, Cynthia, Pyatt, Robert E., Ramirez, Nilsa C., Tabler, Teresa R., Vanhoose, Nathan, White, Peter, Wise, Lisa, Zmuda, Erik, Barnabas, Nandita, Berry-Green, Charlenia, Blanc, Victoria, Boice, Lori, Button, Michael, Farkas, Adam, Green, Alex, MacKenzie, Jean, Nicholson, Dana, Kalloger, Steve E., Blake Gilks, C., Karlan, Beth Y., Lester, Jenny, Orsulic, Sandra, Borowsky, Mark, Cadungog, Mark, Czerwinski, Christine, Huelsenbeck-Dill, Lori, Iacocca, Mary, Petrelli, Nicholas, Rabeno, Brenda, Witkin, Gary, Nemirovich-Danchenko, Elena, Potapova, Olga, Rotin, Daniil, Berchuck, Andrew, Birrer, Michael, DiSaia, Phillip, Monovich, Laura, Curley, Erin, Gardner, Johanna, Mallery, David, Penny, Robert, Dowdy, Sean C., Winterhoff, Boris, Dao, Linda, Gostout, Bobbie, Meuter, Alexandra, Teoman, Attila, Dao, Fanny, Olvera, Narciso, Bogomolniy, Faina, Garg, Karuna, Soslow, Robert A., Levine, Douglas A., Abramov, Mikhail, Bartlett, John M. S., Kodeeswaran, Sugy, Parfitt, Jeremy, Moiseenko, Fedor, Clarke, Blaise A., Goodman, Marc T., Carney, Michael E., Matsuno, Rayna K., Fisher, Jennifer, Huang, Mei, Kimryn Rathmell, W., Thorne, Leigh, Van Le, Linda, Dhir, Rajiv, Edwards, Robert, Elishaev, Esther, Zorn, Kristin, Goodfellow, Paul J., Mutch, David, Kahn, Ari B., Bell, Daphne W., Pollock, Pamela M., Wang, Chen, A.Wheeler, David, Shinbrot, Eve, Ayala, Brenda, Chu, Anna L., Jensen, Mark A., Kothiyal, Prachi, Pihl, Todd D., Pontius, Joan, Pot, David A., Snyder, Eric E., Srinivasan, Deepak, Mills Shaw, Kenna R., Sheth, Margi, Davidsen, Tanja, Eley Martin L. Ferguson, Greg, Demchok, John A., Yang, Liming, Guyer, Mark S., Ozenberger, Bradley A., and Sofia, Heidi J.

Published
2013
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results